Brazil ends retinol survey, screening to follow:
This article was originally published in Clinica
Executive Summary
Brazil's healthcare regulatory authority - Agencia Nacional de Vigilancia Sanitaria (Anvisa) - has concluded its survey of laboratories capable of performing serum retinol testing, as part of a national exercise to map iron-deficiency anaemia. The survey conducted for the national network of pathology laboratories (Reblas) ended on January 30, after having been extended at least twice since its launch in early October 2004 (see Clinica No 1129, p 13); its initial deadline was mid-November. The chosen laboratories will be contracted to support the screening exercise, which will involve 5,000 women aged 15-49 years and 5,000 children under the age of five; Anvisa has not announced further details.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.